Tag Archives: Zydus Cadila

Cadila gets USFDA nod to market blood-pressure, heart disease treatment drug

AHMEDABAD | MUMBAI | RAJKOT – In a press-release submitted to the Indian Stock Exchanges, Ahmedabad headquartered pharma major Cadila Healthcare Ltd (Dr. Pankaj Patel led Zydus Cadila Group) said of having got approval from US FDA (Food & Drugs Administration) to market tablets to treat blood-pressure and heart disease. The press-statement, as addressed by

Zydus announces patient enrollment in clinical trials of Saroglitazar

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to the Indian Stock Exchanges, Ahmedabad headquartered Indian Pharma major Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Group) said of having enrolled patient(s) in evidences VII phase 2 clinical trial of Saroglitazar Magnesium. The company-statement submitted to the Indian Bourses, titled – “Zydus

USFDA classifies Zydus Cadila’s Moraiya unit vide Official Action Initiated

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory updates submitted to the Indian Stock Exchanges, Ahmedabad headquartered Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Cadila Group) said of its Moraiya facility categorized vide Official Action Initiated by US FDA (Food & Drugs Administration). The statement submitted by the company to the Indian Bourses

Zydus announces completion of Phase III trial of Saroglitazar Magnesium

AHMEDABAB | MUMBAI | RAJKOT – In a press release submitted to the Indian Stock Exchanges, Ahmedabad headquartered Indian pharma major Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Cadila Group) said of having completed Phase III trials of Saroglitazar Magnesium in Type 2 Diabetes Mellitus. The press release titled, “Zydus Announces Completion of Phase

Zydus Cadila gets USFDA nod to market sedative/hypnotic (sleep disorder treatment drug)

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Indian Bourses, Ahmedabad headquartered Dr. Pankaj Patel led Cadila Healthcare Ltd (Zydus Cadila Group) said of having got nod from US FDA (Food & Drugs Administration) to market drug to treat insomnia (sleep related disorders) The press release submitted by the company

Zydus Cadila completes 3-phased clinical trial enrollment for drug, to cure liver disorder

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Indian Stock Exchanges, Ahmedabad headquartered Zydus Cadila Group (Cadila Healthcare Ltd) said of having completed enrollment for three phase clinical trials of drug used to treat the a progressive disease of the liver – NASH. The press release submitted to the Indian

Zydus Cadila gets USFDA nod to market high blood-pressure treatment drug

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Stock Exchanges in India on Monday, Ahmedabad headquartered Zydus Cadila Group (Cadila Healthcare) said of having received the final approval from the USFDA (United States Food & Drugs Administration) to market Chlorthalidone Tablets USP (US RLD – THALITONE@),25 mg and 50 mg.

Zydus Cadila (Healthcare) gets USFDA nod to market anti-epileptic drug to prevent & control seizures

AHMEDABAD-GANDHINAGAR | MUMBAI | RAJKOT – In a press-release submitted to the Indian Bourses on Monday, Ahmedabad headquartered pharma major – Cadila Healthcare Ltd (Dr Pankaj Patel led Zydus Cadila Group) has received the tentative approval from the USFDA to market Lacosamide Tablets (US RLD – Vimpat®) in the strengths of 50 mg, 100 mg,

USFDA concludes Cadila Healthcare’s (Zydus) Pharmez facility with one observation

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to the Indian Bourses, on Wednesday, Ahmedabad headquartered Pharma major Cadila Healthcare (Dr Pankaj Patel led Zydus Cadila Group) Ltd said of one of their units being inspected by US Food & Drugs Administration (USFDA) and the regulator has concluded the inspection with one

Cadila Healthcare (Zydus) gets USFDA nod to market tabs to cure urniery tract disorders

AHMEDABAD | MUMBAI | RAJKOT – In a regulatory filing submitted to the Indian Bourses, Ahmedabad headquartered Zydus Cadila has received the tentative approval from the USFDA to market Mirabegron Extended-Release Tablets (US RLD- Myrbetriq® Extended-Release Tablets), 25 mg and 50 mg. Mirabegron is selective beta 3-adrenoceptor agonist approved for the treatment of Overactive Bladder

Zydus Cadila gets USFDA nod, to market tablets, to treat high blood-pressure in lungs

AHMEDABAD | MUMBAI | RAJKOT – In a press-release submitted to the Indian Bourses, Ahmedabad headquartered pharma major – Cadila Healthcare Ltd (Dr Pankaj Patel owned Zydus Cadila Group) said of having received final approval from the US Food & Drugs Administration (USFDA) for Ambrisentan Tablets. The Company has received the final approval from the

Zydus Cadila gets USFDA nod to market erectile dysfunction treatment tabs

AHMEDABAD | MUMBAI | RAJKOT – Zydus Cadila announced the Day 1 launch of Tadalafil Tablets USP (US RLD – Cialis Tablets) upon receiving the final approval from the US FDA for marketing the product in the strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. Manufactured at the group’s manufacturing facility at Moraiya,

USFDA inspects Zydus Cadila’s subsidiary co, issues one observation

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Indian Bourses, Ahmedabad headquartered Cadila Healthcare Ltd said of its USFDA conducted a Pre-Approval Inspection (PAI) for Doxorubicin Liposomal, a complex oncological injectable at Alidac Pharmaceuticals Ltd., the injectable onco manufacturing facility, located at Pharmez, Ahmedabad from 18th to 26th March, 2019.

Zydus Cadila gets USFDA nod to market drugs to treat cholesterol and body tissues

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Exchanges in India, Ahmedabad headquartered and Dr Pankaj Patel led Cadila Healthcare Ltd (Zydus Cadila Group) said of having got US Food & Drugs Administration’s nod to market drug two drugs, one to control cholesterol as well another to treat abnormal hardening

Zydus Cadila gets USFDA nod to market drug to treat excess iron levels in human blood

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Indian Exchanges on Tuesday, Ahmedabad headquartered and Pankaj Patel owned Cadila Healthcare (Zydus Cadila Group) said of having got US Food and Drugs Administration nod to market drug to treat excess iron levels in human blood. Zydus Cadila has received the tentative

Zydus Cadila gets US FDA nod to market drug for treatment of epilepsy

AHMEDABAD | MUMBAI | RAJKOT – In a press release submitted to the Indian Bourses on Tuesday, Cadila Healthcare Ltd (Dr Pankaj Patel owned Zydus Cadila group) said of having availed regulatory approval from US Food and Drugs Administration (USFDA) to market drug to treat epilepsy. Zydus Cadila has received the final approval from the

Do NOT follow this link or you will be banned from the site!